Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track UNCY with free AI briefings, catalyst countdowns, and dilution alerts.

UNCY · Unicycive Therapeutics, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$61.4M Cash on Hand
26.6mo Cash Runway
Follow UNCY by email Get an email when UNCY reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about UNCY, unsubscribe in one click. Privacy

💊 Upcoming FDA Decisions

PDUFA DateDrugIndicationTypePoA
2027-03-25 oxylanthanum carbonate (OLC) NDA 59%

PoA = estimated probability of approval: base rates calibrated against BioRadar's verified FDA outcomes, adjusted for application type, modality, therapy area, cash runway and problems the FDA has raised with the application, as the company has disclosed them. Not investment advice. See the full PDUFA calendar →

📣 What UNCY Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Oxylanthanum Carbonate Chronic Kidney Disease Requiring Chronic Dialysis Phase 2 · NCT06218290 Completed

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

UNCY holds $61.4M in cash and short-term investments (as of Jun 30, 2026) and burns about $6.9M/quarter from operations, an estimated runway of 26.6 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 47 · Elevated

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when UNCY files for a raise →

👥 Who Owns UNCY

Insiders 6.1% Other 5%+ holders 17.4% Institutions (124 holders) 43.8% Public and other holders 32.7%
HolderTypeShares% of sharesAs of
Vivo Opportunity Fund Holdings, L.P. 5%+ holder (13G) 3,911,375 13.40% 2026-09-30
Nantahala Capital Management, LLC Institution (13G, 5%+) 2,807,830 9.62% 2026-06-30
RA Capital Management, L.P. Institution (13G, 5%+) 2,801,082 9.60% 2026-03-31
Gaurav Aggarwal
Director · +42,319 options
Insider 1,789,915 6.13% 2025-08-25
BlackRock, Inc. Institution (13G, 5%+) 1,413,381 4.84% 2026-06-30
Integrated Core Strategies (US) LLC 5%+ holder (13G) 1,172,667 4.02% 2026-01-16

Share count 29,184,509 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

📅 Past FDA Decisions & Stock Reactions

DateDrugTypeRun-up 30dDecision 1dAfter 5d
2026-09-29 — NDA -15.6% -1.9% —
2026-06-29 Oxylanthanum Carbonate (OLC) NDA +0.9% +8% —
2025-10-28 — NDA +30.4% -9.9% -15.3%
2025-06-28 — NDA +11.3% -29.9% -31%

Browse all historical PDUFA outcomes →

Get the full UNCY picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for UNCY and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.